Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative hydrocortisone in pancreatoduodenectomy (PD-HYDRA)
2024-517877-26-00Phase 3Authorised
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in None comparing Hydrocortisone arm with Placebo arm (2 arms). Primary endpoint: Post-operative pancreatic fistula (POPF) grade B or worse within 90 days after surgery. Planned start Mar 2025; status: authorised.
02
Drugs
hydrocortisone
Beyond the preview
Go deeper on 2024-517877-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517877-26-00.